Can Oxandrolone be combined with SARMs in the same cycle?

Yes — Oxandrolone and SARMs operate through complementary mechanisms and can be run concurrently. SARMs provide tissue-selective partial AR agonism, while Oxandrolone delivers full androgen receptor activation and clinically documented nitrogen retention that no currently available SARM replicates at equivalent doses. The combination extends total receptor pathway coverage without introducing a second fully androgenic compound into the stack.

Which SARMs pair most effectively with a 10 mg Oxandrolone tablet format?

Ostarine (MK-2866) and LGD-4033 are the most frequently reported SARM partners for Oxandrolone in community and clinical literature. Ostarine's modest suppressive profile keeps the hormonal load low when stacked with Oxandrolone at 10–20 mg/day. LGD-4033's stronger anabolic signal creates a higher-output pairing suited to intermediate practitioners who have baseline bloodwork confirming normal liver enzyme and lipid values before starting.

What monitoring should I run when stacking SARMs with Oxandrolone?

Baseline bloodwork covering ALT, AST, total cholesterol, HDL and testosterone should be completed before the cycle starts. Retest the hepatic panel at week four, because Oxandrolone's 17α-methyl structure generates a defined liver-enzyme burden that is additive with any SARM-related hepatic modulation. Lipid panels require equal priority: HDL suppression under Oxandrolone is independently confirmed in controlled studies, and SARM co-administration may compound the effect.

Is the 10 mg strength of NordiXanol a practical advantage when building a SARM combination protocol?

Directly, yes. The 10 mg unit represents the lowest commercially uniform tablet strength in the Oxandrolone segment, enabling single-tablet entry doses that keep Oxandrolone's contribution measurable but conservative when introduced alongside a running SARM. Practitioners can titrate upward in exact 10 mg steps in response to tolerance and bloodwork data without the dosing error introduced by splitting higher-strength tablets.

How are NordiXanol tablets supplied and is the format suitable for multi-week SARM stacks?

NordiXanol is supplied as a 100-tablet pack at 10 mg per tablet — 1,000 mg of total Oxandrolone per unit. At a conservative SARM-stack entry dose of 10 mg/day, one pack covers a full ten-week phase; at 20 mg/day alongside a SARM cycle, the pack covers five weeks with no need to split tablets. The blister or jar format preserves tablet integrity and uniformity across the full duration of use. (2) angle_used

Trusted Brand

Nordi Pharma

NordiXanol 10mg/tab 100 Tabletten by Nordi Pharma

Name: NordiXanol 10mg/tab 100 Tablets by Nordi Pharma
Brand: Nordi Pharma
SKU: ORA-OXAN-NOR-017
Price: 50.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

NordiXanol is a precision-dosed oral anabolic tablet delivering Oxandrolone at 10 mg per unit across a 100-tablet pack, specifically positioned here as the androgen-receptor complement to selective androgen receptor modulator (SARM) protocols. Where SARMs engage tissue-selective receptor pathways with partial agonism, Oxandrolone brings full AR occupancy and established nitrogen-retention data, filling a mechanistic gap that no SARM currently covers with equivalent clinical evidence. Each production lot undergoes content-uniformity verification by HPLC at the individual tablet level, with endotoxin screening completed via LAL methodology and GMP-standard process controls applied throughout.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers full androgen receptor activation to complement the tissue-selective partial agonism of SARMs in the same cycle
10 mg per tablet enables precise single-step dose adjustments throughout a graduated SARM-stack titration
Clinically documented nitrogen-retention profile fills the metabolic gap that SARMs alone cannot close
100-tablet count supports phase lengths from five to ten weeks without mid-cycle reorder at typical SARM-stack Oxandrolone doses
No estrogenic conversion pathway — ancillary management within a SARM combination focuses exclusively on androgenic and hepatic endpoints
HPLC content-uniformity testing at the individual tablet level ensures pharmacological reliability at every dose increment
GMP-controlled production with LAL endotoxin clearance documentation available at the batch level

Phase	dosage	Note
SARM Kickstart Entry	10 mg/day (1 tablet)	Introduce Oxandrolone after the SARM dose has stabilised (typically week 2 of the SARM phase); confirm baseline ALT/AST before starting
SARM Mid-Cycle Lean Consolidation	20 mg/day (2 tablets, split AM/PM)	Advance to 20 mg only after week-4 hepatic panel confirms ALT/AST within reference range; most common dose tier in Ostarine and LGD-4033 combinations
Experienced SARM–Oxandrolone Stack	30 mg/day (3 tablets, split across 3 windows)	Reserved for practitioners with prior bloodwork confirmation of hepatic and lipid tolerability; co-administer NAC or TUDCA and monitor HDL closely
SARM Phase Wind-Down / Step-Down	10 mg/day (1 tablet)	Reduce Oxandrolone one tablet at a time in the final week of the SARM phase to allow partial receptor recovery before both compounds are discontinued

Key takeaways

Pair Oxandrolone with SARMs to cover complementary androgen-receptor pathway layers simultaneously.
Choose 10 mg entry doses when introducing Oxandrolone into an active SARM protocol.
Monitor ALT, AST and HDL at baseline and week four during any SARM–Oxandrolone stack.
Confirm bloodwork normality before escalating Oxandrolone beyond 20 mg/day within a SARM phase.
Leverage the 100-tablet pack for flexible phase lengths from five to ten weeks.

Oxandrolone as the Full-Agonist Anchor in SARM-Inclusive Protocols

NordiXanol delivers Oxandrolone — a clinically characterised, full androgen receptor agonist — at the 10 mg tablet format most compatible with precision titration inside multi-compound SARM stacks. SARMs such as Ostarine (MK-2866), LGD-4033 and RAD-140 bind the androgen receptor selectively, producing tissue-preferential anabolic signalling without full androgenic activation; Oxandrolone, by contrast, drives complete AR transcriptional output in both skeletal muscle and bone matrix, a difference confirmed in receptor-occupancy studies comparing selective versus non-selective ligands. The two compound classes therefore occupy complementary mechanistic positions rather than redundant ones, which is the foundational logic of a SARM–Oxandrolone combination.

Why Oxandrolone Fills the Gap SARMs Leave Open

SARMs achieve tissue selectivity partly by producing incomplete coactivator recruitment compared to steroidal full agonists; this selectivity advantage carries a corresponding ceiling on anabolic output per milligram. Oxandrolone removes that ceiling specifically in the nitrogen-retention domain: controlled clinical trials in burn-recovery populations document a sustained positive nitrogen balance under Oxandrolone administration that no currently approved SARM has matched in head-to-head metabolic measurements. NordiXanol's 10 mg unit allows practitioners to introduce Oxandrolone at conservative entry doses — typically 10–20 mg/day — alongside a running SARM phase, keeping the total suppressive load modest while adding a layer of anabolic signalling the SARM alone cannot replicate.

Stack Architecture and Monitoring Priorities

A structured SARM–Oxandrolone stack assigns each compound a distinct functional role: the SARM supplies tissue-selective receptor engagement with reduced androgenic side-load, while Oxandrolone contributes verified nitrogen economy and lean-tissue density through full AR activation. Compared to a SARM-only protocol at equivalent daily commitment, the combined approach delivers broader receptor pathway coverage without stacking a second fully androgenic compound. Monitoring priorities shift when the two classes run together: LFT panels (ALT/AST) should be assessed at baseline and at week four, because Oxandrolone's 17α-methyl structure places a defined burden on hepatic enzyme systems even at moderate doses; lipid panels warrant equal attention, as HDL suppression under Oxandrolone is additive with any SARM-driven hormonal modulation. The 100-tablet pack at 10 mg provides operational flexibility across both short SARM kickstart phases and longer lean-consolidation windows.

Usage

Complete a full baseline blood panel — ALT, AST, total cholesterol, HDL, LDL, testosterone — before starting NordiXanol alongside any SARM.
Allow the SARM dose to reach approximate steady-state (typically 10–14 days into the SARM phase) before introducing the first 10 mg Oxandrolone tablet, so each compound's independent contribution can be assessed.
Swallow tablets whole with water and a small meal to support consistent gastric absorption; avoid co-administration with grapefruit juice, which modulates CYP enzyme activity relevant to oral steroid clearance.
Split the daily Oxandrolone dose across two or three evenly spaced windows (e.g., morning and early afternoon at 20 mg/day) to maintain steady plasma exposure without late-evening dosing that may interfere with nocturnal hormonal rhythms.
Rerun hepatic and lipid panels at week four of the combined stack; if ALT or AST exceeds 2× the upper limit of normal, reduce the Oxandrolone dose by one tablet and reassess before continuing.
Plan a structured PCT or hormonal recovery protocol to begin within 48–72 hours of the final SARM and Oxandrolone dose, using SERM therapy as indicated by end-of-cycle testosterone suppression data.

Warnings

Contraindications: NordiXanol is contraindicated in individuals with pre-existing hepatic impairment, carcinoma of the prostate or breast, hypercalcaemia, or known hypersensitivity to Oxandrolone. Women of childbearing potential should not use this product. Do not initiate a SARM–Oxandrolone stack without a documented baseline blood panel confirming normal liver enzyme and lipid values.

Side Effects: Hepatotoxicity risk is present due to 17α-methylation; severity is dose- and duration-dependent. HDL cholesterol suppression has been quantified at 21–33% in controlled clinical settings and may be compounded by concurrent SARM use. Additional potential effects include mild HPG-axis suppression, transient haematocrit changes, and androgenic responses (acne, scalp sensitivity) in predisposed individuals.

Monitoring: Assess ALT, AST, total cholesterol and HDL at baseline, week four, and end of cycle as a minimum monitoring schedule. When Oxandrolone runs alongside a SARM, haematocrit and serum testosterone should be added to the panel. Any ALT/AST result exceeding twice the laboratory upper reference limit is a clinical signal to discontinue or reduce dose immediately.

PCT: Post-cycle therapy with a SERM (clomiphene or tamoxifen) is recommended following any Oxandrolone cycle, including those run within a SARM stack, if end-of-cycle testosterone levels fall below the lower reference range. Initiate PCT 48–72 hours after the last tablet. Duration is guided by serial testosterone recovery bloodwork rather than a fixed calendar schedule.

Frequently asked questions

Can Oxandrolone be combined with SARMs in the same cycle?: Yes — Oxandrolone and SARMs operate through complementary mechanisms and can be run concurrently. SARMs provide tissue-selective partial AR agonism, while Oxandrolone delivers full androgen receptor activation and clinically documented nitrogen retention that no currently available SARM replicates at equivalent doses. The combination extends total receptor pathway coverage without introducing a second fully androgenic compound into the stack.
Which SARMs pair most effectively with a 10 mg Oxandrolone tablet format?: Ostarine (MK-2866) and LGD-4033 are the most frequently reported SARM partners for Oxandrolone in community and clinical literature. Ostarine's modest suppressive profile keeps the hormonal load low when stacked with Oxandrolone at 10–20 mg/day. LGD-4033's stronger anabolic signal creates a higher-output pairing suited to intermediate practitioners who have baseline bloodwork confirming normal liver enzyme and lipid values before starting.
What monitoring should I run when stacking SARMs with Oxandrolone?: Baseline bloodwork covering ALT, AST, total cholesterol, HDL and testosterone should be completed before the cycle starts. Retest the hepatic panel at week four, because Oxandrolone's 17α-methyl structure generates a defined liver-enzyme burden that is additive with any SARM-related hepatic modulation. Lipid panels require equal priority: HDL suppression under Oxandrolone is independently confirmed in controlled studies, and SARM co-administration may compound the effect.
Is the 10 mg strength of NordiXanol a practical advantage when building a SARM combination protocol?: Directly, yes. The 10 mg unit represents the lowest commercially uniform tablet strength in the Oxandrolone segment, enabling single-tablet entry doses that keep Oxandrolone's contribution measurable but conservative when introduced alongside a running SARM. Practitioners can titrate upward in exact 10 mg steps in response to tolerance and bloodwork data without the dosing error introduced by splitting higher-strength tablets.
How are NordiXanol tablets supplied and is the format suitable for multi-week SARM stacks?: NordiXanol is supplied as a 100-tablet pack at 10 mg per tablet — 1,000 mg of total Oxandrolone per unit. At a conservative SARM-stack entry dose of 10 mg/day, one pack covers a full ten-week phase; at 20 mg/day alongside a SARM cycle, the pack covers five weeks with no need to split tablets. The blister or jar format preserves tablet integrity and uniformity across the full duration of use. (2) angle_used

Manufacturer

Nordi Pharma's approach to NordiXanol reflects a deliberate investment in the competence and training of its pharmaceutical development team rather than in brand marketing infrastructure alone. The personnel responsible for tablet formulation, API sourcing qualification and QC release protocols operate within a knowledge framework that requires direct familiarity with content-uniformity requirements specific to low-strength oral anabolics — a technically demanding category where per-tablet API variance carries greater pharmacological consequence than in higher-dose formats. Staff expertise is applied at the formulation stage to optimise excipient selection and compression parameters that protect homogeneity across the full 100-tablet unit, and at the QC stage to execute HPLC content-uniformity testing and LAL endotoxin screening before any lot is released. The outcome of this human-capital investment is a product whose batch-to-batch reproducibility is traceable through release documentation accessible to purchasers on request.

Product details

Brand	Nordi Pharma
Active ingredient	oxandrolone
Also known as	Anavar, Oxandrin, Oxandrolone, NordiXanol, Nordi Pharma Anavar
Strength	10 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-OXAN-NOR-017

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starsironVerified purchaseAug 6, 2026
Anavar that actually works
50mg ed for 8 weeks, body recomp run. Dropped from 14% to around 10.5% bf by DEXA, weight barely changed which tells you everything. Vascularity came in around week 4. No joint issues, no aggression, lipids stayed reasonable. Tabs dosed consistently, no pip concerns obviously. Shipping was fast and discreet. Top quality
Rating: 4 out of 5 starsfortitudeVerified purchaseJun 26, 2026
good var, pricey though
ran 30mg ed for 10 weeks alongside a low test base. Strength went up noticeably and I leaned out well, probably dropped 3kg of fat while keeping all my muscle. Only gripe is the price per tab adds up fast on a longer run. Tabs are also quite small and a bit fiddly to split if you want 15mg doses. Results are solid though, wouldn't hesitate to use agian

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Oxandrolon 10mg/tab 100 Tablets by Balkan Pharmaceuticals

Lab Tested

Oxandrolon 10mg/tab 100 Tabletten by Balkan Pharmaceuticals

Oxandrolon by Balkan Pharmaceuticals is a 17α-alkylated dihydrotestosterone-derived oral anabolic agent — each tablet delivering 10 mg of Oxandrolone — distinguished by its selective anabolic signalling profile that produces measurable nitrogen retention with markedly reduced androgenic transactivation compared to testosterone. The compound triggers genomic pathways at the nuclear receptor level, upregulating skeletal muscle protein synthesis without the estrogenic conversion characteristic of non-DHT-derived steroids. Quality is enforced at the batch level: HPLC-verified active-ingredient quantification and LAL endotoxin testing are applied to every production run at Balkan Pharmaceuticals' GMP-certified Chișinău facility.

€52.00

Anavar-Lite 10mg/tab 50 Tablets by Beligas Pharmaceuticals

HPLC Verified

Anavar-Lite 10mg/tab 50 Tabletten by Beligas Pharmaceuticals

Anavar-Lite by Beligas Pharmaceuticals delivers Oxandrolone at a precisely controlled 10 mg per tablet across a 50-tablet supply, defined by its predictable oral pharmacokinetic profile — an elimination half-life of approximately 9–10 hours that supports twice-daily dosing without plasma level fluctuations. The 10 mg unit dose is particularly suited to users who require granular titration, whether ramping into a cycle or tapering at its conclusion. HPLC quantification of every production batch — cross-referenced against certified reference standards — confirms that each tablet's declared concentration is analytically exact, providing a reliable foundation for plasma-level management throughout the full cycle window.

€48.00

Pro-Anavar 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anavar 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anavar is an oral Oxandrolone preparation dosed at 50 mg per tablet — the highest concentration available in this product group — formulated to deliver clinically relevant anabolic activity through the gastrointestinal route, where first-pass hepatic metabolism defines how much active compound ultimately reaches systemic circulation. Because Oxandrolone is administered orally rather than by injection, its absolute bioavailability (approximately 97% of the absorbed fraction, per published pharmacokinetic data) is notably high for an oral steroid, a distinction rooted in the 17α-methyl structural modification that curtails hepatic inactivation. Batch-release quality is enforced by HPLC quantification against certified reference standards; LAL endotoxin screening covers all excipient inputs — every 50-tablet jar reflects Beligas Pharmaceuticals' documented Pharma Grade manufacturing framework.

€90.00

OxaTrex 10mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxaTrex 10mg/tab 100 Tabletten by Concentrex Labs

OxaTrex delivers Oxandrolone at 10 mg per tablet across a 100-tablet supply, distinguished by its documented influence on peripheral insulin sensitivity and substrate utilisation — making it a precision metabolic tool rather than a simple strength agent. Compared to higher-concentration oral formats, the 10 mg unit dose supports granular, day-by-day titration aligned with individual glucose response. Every batch leaving the Concentrex Labs facility is subject to HPLC potency assay at finished-product stage and endotoxin screening via the LAL method; GMP-compliant production records accompany each released lot.

€70.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00